Uric Acid Dynamics in Gestational Hypertensive Disorders

Uric acid, the end product of purine metabolism, has long been recognised as both a marker and a mediator in the spectrum of hypertensive disorders emerging in pregnancy. Levels typically rise in the third trimester under normal physiological adaptations, but in gestational hypertension and pre-eclampsia these elevations are accentuated and often precede clinical presentation. Mechanistically, impaired renal clearance, oxidative stress and endothelial dysfunction converge to elevate circulating urate. Endothelial injury reduces nitric oxide bioavailability, while oxidative pathways both generate and are amplified by uric acid, creating a feed-forward loop that exacerbates vascular resistance. At the placental interface, altered angiogenic balance—characterised by shifts in placental growth factor and soluble fms-like tyrosine kinase-1—further perturbs urate homeostasis and contributes to placental insufficiency. Clinically, serial measurement of maternal serum uric acid, often indexed to creatinine, enhances early risk stratification for adverse maternal and neonatal outcomes, including preterm birth, intrauterine growth restriction and perinatal morbidity. As a low-cost and widely available analyte, uric acid dynamics offer a practical adjunct to current screening algorithms, guiding intensified surveillance and timely intervention. Continued elucidation of uric acid’s pathophysiological roles promises novel therapeutic targets, from xanthine oxidase inhibition to antioxidant protocols, aimed at mitigating hypertensive complications in pregnancy.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Uric Acid Dynamics in Gestational Hypertensive Disorders publication trend

The graph below shows the total number of articles in uric acid dynamics in gestational hypertensive disorders across all publications each year (not limited to Nature Index journals).

Technical terms

Uric acid: Final product of purine degradation, elevated in impaired renal clearance and oxidative stress.

Preeclampsia: Pregnancy-specific syndrome defined by new-onset hypertension and end-organ dysfunction after 20 weeks’ gestation.

Gestational hypertension: New-onset hypertension in pregnancy without proteinuria or systemic features of preeclampsia.

Endothelial dysfunction: Impaired vascular endothelium leading to reduced vasodilatation and pro-inflammatory state.

Oxidative stress: Imbalance favouring reactive oxygen species over antioxidant defences, contributing to vascular injury.

Angiogenic factors: Molecules such as placental growth factor and soluble fms-like tyrosine kinase-1 that regulate placental blood vessel development.

Serum uric acid to creatinine ratio: Indexed measure adjusting urate concentration for renal excretion capacity.

Mendelian randomisation: Genetic epidemiology method using inherited variants to infer causal relationships between exposures and outcomes.

References

1. Serum uric acid to creatinine ratio and risk of preeclampsia and adverse pregnancy outcomes. Journal of Hypertension (2023).
2. Causal pathways in preeclampsia: a Mendelian randomization study in European populations. Frontiers in Endocrinology (2024).
3. Impact of Angiogenic and Cardiovascular Biomarkers for Prediction of Placental Dysfunction in the First Trimester of Pregnancy. Biomedicines (2023).